FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326607220> ?p ?o ?g. }

• W2326607220 endingPage "24" @default.
• W2326607220 startingPage "24" @default.
• W2326607220 abstract "The prevalence of OTC aspirin use is unknown, but with all the publicity about its potential benefit for cardiovascular health and cancer prevention, it's wise to assume many of your patients are using it. Recent data regarding aspirin therapy reinforce the need to evaluate potential benefits and risks in each patient. A recent study evaluated the overall benefit of aspirin use for primary prevention of cardiovascular events.1.JAMA. 2012;307(21):2286–94.Google Scholar Data for patients with and without diabetes who were taking placebo or aspirin were evaluated to determine the incidence of hospitalization for major bleeds (cerebral hemorrhage or gastrointestinal bleeds). The aspirin dose was less than 300 mg daily, and patient data were collected for a period of approximately 6 years. The researchers found that those taking aspirin and those with diabetes (regardless of aspirin use) had a significantly higher incidence of one of the adverse outcomes. These data reinforce the opportunities for pharmacists to counsel patients on the use of aspirin and potential risks to keep in mind. The data also suggest that individuals with diabetes, regardless of aspirin use, might benefit from a brief conversation about watching for increased risk of bleeding. The most recent guidelines for aspirin use from the American Diabetes Association suggested using low-dose aspirin (75–162 mg) as primary prevention for cardiovascular disease (CVD) in individuals with type 1 or type 2 diabetes and a 10-year cardiovascular risk greater than 10%.2.http://care.diabetesjournals.orgcontent/36/Supplement_1/S4.full.Google Scholar This would include most men older than 50 years and women older than 60 years with at least one additional risk factor (e.g., dyslipidemia, hypertension). Clinical judgment regarding the use of aspirin is recommended for those with a 10-year cardiovascular risk of 5% to 10%. Low-dose aspirin for secondary prevention also is recommended in patients with diabetes who have a history of CVD. Often the only evidence of aspirin's antiplatelet activity is increased bruising or bleeding. A recent evaluation was completed to determine if enteric coating/absorption affected response.3.Circulation. 2013;127(3):377–85Google Scholar A total of 400 patients took 325 mg aspirin in either immediate-release (IR) or enteric-coated (EC) formulation. Cyclooxygenase-1 activity was measured to evaluate response. Approximately 50% of patients taking 325 mg EC aspirin appeared to have aspirin resistance compared with no resistance among those taking the IR product. However, subsequent analysis revealed that rather than resistance, the issue was related to the type of aspirin used and the timing of administration. This study suggested that the IR formulation should be used to ensure absorption, and ultimately therapeutic benefit of antiplatelet activity, especially in patients using aspirin for secondary prevention only. CVD is the leading cause of death in women; thus, many are told to take aspirin for either primary or secondary prevention. In 2004 (survey 1) and 2009 (survey 2), women from 127 facilities were assessed for health attributes, including CVD risk factors and aspirin use.4.J Womens Health (Larchmt). 2012;21(4):379–87Google Scholar Slightly more than 218,000 women responded to the surveys, and 29,701 were told by their health care provider to take aspirin based on their profile and guidelines. The results showed that 41% of women who met criteria for primary prevention were taking aspirin as recommended, while 48% who met criteria for secondary prevention were taking aspirin as recommended. From survey 1 to survey 2, a significant increase was seen in use for primary prevention, but no change was seen in use for secondary prevention. These data suggest that pharmacists have an opportunity to identify women who should be using aspirin and educate those for whom aspirin therapy is recommended." @default.
• W2326607220 created "2016-06-24" @default.
• W2326607220 creator A5067055492 @default.
• W2326607220 date "2014-01-01" @default.
• W2326607220 modified "2023-10-14" @default.
• W2326607220 title "Aspirin therapy: Evaluating benefits and risks" @default.
• W2326607220 cites W1986075319 @default.
• W2326607220 cites W2137806740 @default.
• W2326607220 doi "https://doi.org/10.1016/s1042-0991(15)31013-6" @default.
• W2326607220 hasPublicationYear "2014" @default.
• W2326607220 type Work @default.
• W2326607220 sameAs 2326607220 @default.
• W2326607220 citedByCount "0" @default.
• W2326607220 crossrefType "journal-article" @default.
• W2326607220 hasAuthorship W2326607220A5067055492 @default.
• W2326607220 hasBestOaLocation W23266072201 @default.
• W2326607220 hasConcept C120665830 @default.
• W2326607220 hasConcept C121332964 @default.
• W2326607220 hasConcept C126322002 @default.
• W2326607220 hasConcept C134018914 @default.
• W2326607220 hasConcept C142724271 @default.
• W2326607220 hasConcept C177713679 @default.
• W2326607220 hasConcept C204787440 @default.
• W2326607220 hasConcept C27081682 @default.
• W2326607220 hasConcept C2777180221 @default.
• W2326607220 hasConcept C2777628954 @default.
• W2326607220 hasConcept C2779134260 @default.
• W2326607220 hasConcept C2993857929 @default.
• W2326607220 hasConcept C555293320 @default.
• W2326607220 hasConcept C61511704 @default.
• W2326607220 hasConcept C71924100 @default.
• W2326607220 hasConceptScore W2326607220C120665830 @default.
• W2326607220 hasConceptScore W2326607220C121332964 @default.
• W2326607220 hasConceptScore W2326607220C126322002 @default.
• W2326607220 hasConceptScore W2326607220C134018914 @default.
• W2326607220 hasConceptScore W2326607220C142724271 @default.
• W2326607220 hasConceptScore W2326607220C177713679 @default.
• W2326607220 hasConceptScore W2326607220C204787440 @default.
• W2326607220 hasConceptScore W2326607220C27081682 @default.
• W2326607220 hasConceptScore W2326607220C2777180221 @default.
• W2326607220 hasConceptScore W2326607220C2777628954 @default.
• W2326607220 hasConceptScore W2326607220C2779134260 @default.
• W2326607220 hasConceptScore W2326607220C2993857929 @default.
• W2326607220 hasConceptScore W2326607220C555293320 @default.
• W2326607220 hasConceptScore W2326607220C61511704 @default.
• W2326607220 hasConceptScore W2326607220C71924100 @default.
• W2326607220 hasIssue "1" @default.
• W2326607220 hasLocation W23266072201 @default.
• W2326607220 hasOpenAccess W2326607220 @default.
• W2326607220 hasPrimaryLocation W23266072201 @default.
• W2326607220 hasRelatedWork W2046843022 @default.
• W2326607220 hasRelatedWork W2100079448 @default.
• W2326607220 hasRelatedWork W2101354101 @default.
• W2326607220 hasRelatedWork W2112172095 @default.
• W2326607220 hasRelatedWork W2121168431 @default.
• W2326607220 hasRelatedWork W2474699632 @default.
• W2326607220 hasRelatedWork W2531454911 @default.
• W2326607220 hasRelatedWork W3158431806 @default.
• W2326607220 hasRelatedWork W4238089809 @default.
• W2326607220 hasRelatedWork W4293065854 @default.
• W2326607220 hasVolume "20" @default.
• W2326607220 isParatext "false" @default.
• W2326607220 isRetracted "false" @default.
• W2326607220 magId "2326607220" @default.
• W2326607220 workType "article" @default.